Lungs don’t speak, but they tell a story.

Every breath holds a secret of resilience, of science pushing forward, of lives changed by innovation. At I3LUNG, we’re working to unlock that story with AI, data and transform care for those who need it most.

On World Cancer Day, let’s rethink how we listen. Let’s challenge how we act. Because the future of lung cancer care isn’t just about treatments, it’s about understanding.

On January 31st and February 1st, Dr. Arsela Prelaj, (PI) of the I3LUNG project, took the conversation to the next level at the III International Thoracic Cancer Debates. As a speaker in the session Artificial Intelligence in LC from research to clinic: How and When?, she turned the usual question of “when” AI will reach the clinic into “how” we can already use it to transform patient care today.

This event was more than just an exchange of knowledge; it was an opportunity to rewrite the rules of thoracic oncology. AI is not just data and algorithms; it’s the tool that brings us closer to more precise, human, and effective treatment.

As part of the I3LUNG project, we highlight the inspiring presentation by Yvonne Díaz, patient advocate and member of Lung Cancer Europe (LuCE), at the Upsmart conference in Manchester, UK, in November 2024.

In her talk, Yvonne addressed the hopes and concerns of patients regarding the use of technologies such as artificial intelligence, wearables, and other innovations in oncological research.

How can we ensure that patients remain at the center of this new digital world?

A valuable reflection on how technology can transform medical research while keeping the perspectives of those who matter most: the patients.

Discover her perspective here: https://www.youtube.com/watch?v=5YwAnCdl4eA

The Hackathon had the objective of setting up collaborative groups, having them come up with innovative, AI-driven approaches to combat cancer – inspired by real-world cases of AI deployments in cancer practice. The I3LUNG project PI, Arsela Prelaj was one of the faculty members, with colleagues from Politecnico di Milano.

 

The I3LUNG project and the Metropolitan Hospital have been awarded the Gold Prize at the prestigious Healthcare Business Awards, recognizing their outstanding contribution to oncology research.

Gold Prize: Metropolitan Hospital for their exceptional work on the I3LUNG project.
Silver Prize: Hellenic Foundation for Cancer Research for the HERCARE initiative, focused on eliminating hereditary cancer risks.

We also celebrate the achievements of our partners at ΕΟΠΕ – HeSMO:
Gold: Biomarkers Consensus.
Bronze: National Cancer Awareness Campaign.

Congratulations to everyone involved!

At the recent VIII Thoracic Oncology Conference in Bari, the I3LUNG project PI, Arsela Prelaj, took the stage with her presentation, “L’Intelligenza artificiale e le sue applicazioni nei tumori polmonari”. It not only opened the door to the future but showed us that the future is already here.

Innovation never stops!

Last Friday, MEDSIR’s office hosted a meeting for the I3LUNG partners: Vall d’Hebron Institute of Oncology (VHIO), Universitätsklinikum Hamburg Eppendorf, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Istituto Mario Negri and MEDSIR, represented by Caterina Carbonell Núñez, Aina Bursá, Rocío Caro Consuegra, Ronald Simon, MELISSA FERNANDEZ PINTO, Alba Meya Molina, Ramon Amat Ferrer, Monica Ganzinelli, Laura Brunelli and Cecilia Silvestri.

During this working session, the team shared initial results from the first phase of patient analysis and conducted an in-depth brainstorming session focused on integrating innovative techniques to advance the project. They also discussed progress on the OMICs platform and established a timeline for potential results communications in 2025. 

Go, go, GOOO I3LUNG project 💙🫁

During the session on “Ethical and Regulatory Aspects for Implementing AI in Clinical Trials,” Arsela Prelaj, our I3LUNG partner from Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, delivered a talk on “AI for Immuno-Oncology.”

Her presentation highlighted how artificial intelligence is driving advancements in personalized cancer treatments and shaping the future of immunotherapy. A huge step forward for the I3LUNG project and AI-driven solutions in clinical research!

I3LUNG made an appearance at “Cancer Core Europe’s Summer School in Translational Cancer Research 2024”, in Albufeira (Portugal). On October 9, the project was showcased in the AI for oncology session, as one of the use cases presented by Arsela Prelaj to present how AI tools are used for prediction and treatment decision. The week-long event regrouped 70 junior researchers with backgrounds from basic to clinical and computational research.

Arsela Prelaj has presented I3LUNG project during the “Building Bridges to Interconnect People 2024 meeting“, a yearly Italian digital meeting and training event for clinical oncologists aimed at sharing the latest innovations in the fields of diagnostic and treatment.

The project was explained during the October 1st session on “Unlocking the potential of artificialIntelligence in cancer research and care”, with an overview of the wide range of activities conducted by the I3LUNG consortium for the creation of co-decision tools.